Bright Minds Biosciences Inc. (DRUG) Research

Bright Minds Biosciences Inc. is a preclinical biotechnology firm dedicated to creating serotonin-based therapies. Its primary goal is to enhance the well-being of individuals suffering from severe and life-altering conditions. The company's development pipeline includes selective agonists for the 5-HT2C, 5-HT2A, and combined 5-HT2C/A serotonin receptors, which are being explored for potential treatments in epilepsy, pain management, and neuropsychiatric disorders. Bright Minds maintains strategic collaborations with the National Institutes of Health (NIH) for epilepsy research, the University of Texas Medical Branch (UTMB) for impulse control disorders like binge eating, and the Medical College of Wisconsin. The company, incorporated in 2019, operates from its headquarters in Vancouver, Canada.

Market snapshot

Symbol
DRUG
Price
$60.66
Day change
+1.92%
Market cap
$679.8M
P/E ratio
-30.54x
52-week range
23.175-123.75
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$159.5

Peer companies

  • Altimmune, Inc. (ALT)
  • Annexon, Inc. (ANNX)
  • Aura Biosciences, Inc. (AURA)
  • DiaMedica Therapeutics Inc. (DMAC)
  • Design Therapeutics, Inc. (DSGN)
  • enGene Holdings Inc. (ENGN)
  • Galectin Therapeutics Inc. (GALT)
  • I-Mab (IMAB)

Recent insider activity

  • Cormorant Asset Management, LP — S-Sale (109331 shares) on 2026-04-28
  • Cormorant Asset Management, LP — P-Purchase (184331 shares) on 2024-11-04
  • Cormorant Asset Management, LP — P-Purchase (3107 shares) on 2024-10-16
  • Cormorant Asset Management, LP — P-Purchase (7150 shares) on 2024-10-16
  • Cormorant Asset Management, LP — P-Purchase (39743 shares) on 2024-10-16

Open Bright Minds Biosciences Inc. (DRUG) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.